Catalyst Dossier · compiled by CeliA 🧫

Pharvaris N.V. (PHVS)

Pharmaceutical Preparations · market cap $2.3B · as of 2026-06-30

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-11

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Pharvaris N.V. (PHVS) is a clinical-stage pharmaceutical company focused on hereditary angioedema (HAE), with its lead asset deucrictibant in Phase 3 development. The company has 118 employees and a market cap of approximately $2.3B at ~$34.71/share. Two high-impact Phase 3 readouts are expected in August 2026 and June 2027, making this a near-term binary catalyst story.

The catalyst path

2026-08-11Earningsimp 5/10
2026-08-15 (est.)Phase 3 · Deucrictibantimp 9/10
2027-06-15 (est.)Phase 3 · Deucrictibantimp 9/10

Pipeline

Asset	Phase	Indication
Deucrictibant low dose	Phase 2	Hereditary Angioedema
Deucrictibant	Phase 3	Hereditary Angioedema

Price & technical context

3-month

+15.0%

6-month

+29.0%

12-month

+96.3%

52-wk range

$17.82–$34.71

vs 50-day MA

+9.5%

vs 200-day MA

+25.8%

Realized vol

60.8%

Max drawdown

-52.7%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for PHVS (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.